aluates Reports

$ 0.0

Automative

Global Infliximab and Biosimilar Market Research Report 2025

Published Date: August 2025

Report Code: QYRE-Auto-25I6908

Global Infliximab and Biosimilar Market Insights Forecast to 2028

BUY CHAPTERS

Global Infliximab and Biosimilar Market Research Report 2025

Code: QYRE-Auto-25I6908

Report

August 2025

Pages:76

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Janssen Biotech

Pfizer Inc

Merck

Merck and Co.

Infliximab and Biosimilar Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Infliximab and Biosimilar Market

The global market for Infliximab and Biosimilar was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Infliximab and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infliximab and Biosimilar.

The Infliximab and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Infliximab and Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Infliximab and Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Infliximab and Biosimilar Market Report

Report Metric	Details
Report Name	Infliximab and Biosimilar Market
CAGR	5%
Segment by Type	Infliximab Infliximab-dyyb Infliximab-abda
Segment by Application	Crohn's Disease Pediatric Crohn's Disease Ulcerative Colitis Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Plaque Psoriasis
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Janssen Biotech, Merck and Co., Pfizer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Infliximab and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Infliximab and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Infliximab and Biosimilar Market report?

Ans: The main players in the Infliximab and Biosimilar Market are Janssen Biotech, Merck and Co., Pfizer

What are the Application segmentation covered in the Infliximab and Biosimilar Market report?

Ans: The Applications covered in the Infliximab and Biosimilar Market report are Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis

What are the Type segmentation covered in the Infliximab and Biosimilar Market report?

Ans: The Types covered in the Infliximab and Biosimilar Market report are Infliximab, Infliximab-dyyb, Infliximab-abda

Recommended Reports

Autoimmune Disease Markets

Biologics & Biosimilars

Immunology & Inflammatory

1 Infliximab and Biosimilar Market Overview

1.1 Product Definition

1.2 Infliximab and Biosimilar by Type

1.2.1 Global Infliximab and Biosimilar Market Value Comparison by Type (2024 VS 2031)

1.2.2 Infliximab

1.2.3 Infliximab-dyyb

1.2.4 Infliximab-abda

1.3 Infliximab and Biosimilar by Application

1.3.1 Global Infliximab and Biosimilar Market Value by Application (2024 VS 2031)

1.3.2 Crohn's Disease

1.3.3 Pediatric Crohn's Disease

1.3.4 Ulcerative Colitis

1.3.5 Rheumatoid Arthritis

1.3.6 Ankylosing Spondylitis

1.3.7 Psoriatic Arthritis

1.3.8 Plaque Psoriasis

1.4 Global Infliximab and Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Infliximab and Biosimilar Revenue 2020-2031

1.4.2 Global Infliximab and Biosimilar Sales 2020-2031

1.4.3 Global Infliximab and Biosimilar Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Infliximab and Biosimilar Market Competition by Manufacturers

2.1 Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2020-2025)

2.2 Global Infliximab and Biosimilar Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Infliximab and Biosimilar Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Infliximab and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Infliximab and Biosimilar, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Infliximab and Biosimilar, Product Type & Application

2.7 Global Key Manufacturers of Infliximab and Biosimilar, Date of Enter into This Industry

2.8 Global Infliximab and Biosimilar Market Competitive Situation and Trends

2.8.1 Global Infliximab and Biosimilar Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Infliximab and Biosimilar Players Market Share by Revenue

2.8.3 Global Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Infliximab and Biosimilar Market Scenario by Region

3.1 Global Infliximab and Biosimilar Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Infliximab and Biosimilar Sales by Region: 2020-2031

3.2.1 Global Infliximab and Biosimilar Sales by Region: 2020-2025

3.2.2 Global Infliximab and Biosimilar Sales by Region: 2026-2031

3.3 Global Infliximab and Biosimilar Revenue by Region: 2020-2031

3.3.1 Global Infliximab and Biosimilar Revenue by Region: 2020-2025

3.3.2 Global Infliximab and Biosimilar Revenue by Region: 2026-2031

3.4 North America Infliximab and Biosimilar Market Facts & Figures by Country

3.4.1 North America Infliximab and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Infliximab and Biosimilar Sales by Country (2020-2031)

3.4.3 North America Infliximab and Biosimilar Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Infliximab and Biosimilar Market Facts & Figures by Country

3.5.1 Europe Infliximab and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Infliximab and Biosimilar Sales by Country (2020-2031)

3.5.3 Europe Infliximab and Biosimilar Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Infliximab and Biosimilar Market Facts & Figures by Region

3.6.1 Asia Pacific Infliximab and Biosimilar Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Infliximab and Biosimilar Sales by Region (2020-2031)

3.6.3 Asia Pacific Infliximab and Biosimilar Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Infliximab and Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Infliximab and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Infliximab and Biosimilar Sales by Country (2020-2031)

3.7.3 Latin America Infliximab and Biosimilar Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Infliximab and Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Infliximab and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Infliximab and Biosimilar Sales by Country (2020-2031)

3.8.3 Middle East and Africa Infliximab and Biosimilar Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Infliximab and Biosimilar Sales by Type (2020-2031)

4.1.1 Global Infliximab and Biosimilar Sales by Type (2020-2025)

4.1.2 Global Infliximab and Biosimilar Sales by Type (2026-2031)

4.1.3 Global Infliximab and Biosimilar Sales Market Share by Type (2020-2031)

4.2 Global Infliximab and Biosimilar Revenue by Type (2020-2031)

4.2.1 Global Infliximab and Biosimilar Revenue by Type (2020-2025)

4.2.2 Global Infliximab and Biosimilar Revenue by Type (2026-2031)

4.2.3 Global Infliximab and Biosimilar Revenue Market Share by Type (2020-2031)

4.3 Global Infliximab and Biosimilar Price by Type (2020-2031)

5 Segment by Application

5.1 Global Infliximab and Biosimilar Sales by Application (2020-2031)

5.1.1 Global Infliximab and Biosimilar Sales by Application (2020-2025)

5.1.2 Global Infliximab and Biosimilar Sales by Application (2026-2031)

5.1.3 Global Infliximab and Biosimilar Sales Market Share by Application (2020-2031)

5.2 Global Infliximab and Biosimilar Revenue by Application (2020-2031)

5.2.1 Global Infliximab and Biosimilar Revenue by Application (2020-2025)

5.2.2 Global Infliximab and Biosimilar Revenue by Application (2026-2031)

5.2.3 Global Infliximab and Biosimilar Revenue Market Share by Application (2020-2031)

5.3 Global Infliximab and Biosimilar Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Janssen Biotech

6.1.1 Janssen Biotech Company Information

6.1.2 Janssen Biotech Description and Business Overview

6.1.3 Janssen Biotech Infliximab and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Janssen Biotech Infliximab and Biosimilar Product Portfolio

6.1.5 Janssen Biotech Recent Developments/Updates

6.2 Merck and Co.

6.2.1 Merck and Co. Company Information

6.2.2 Merck and Co. Description and Business Overview

6.2.3 Merck and Co. Infliximab and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Merck and Co. Infliximab and Biosimilar Product Portfolio

6.2.5 Merck and Co. Recent Developments/Updates

6.3 Pfizer

6.3.1 Pfizer Company Information

6.3.2 Pfizer Description and Business Overview

6.3.3 Pfizer Infliximab and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Pfizer Infliximab and Biosimilar Product Portfolio

6.3.5 Pfizer Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Infliximab and Biosimilar Industry Chain Analysis

7.2 Infliximab and Biosimilar Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Infliximab and Biosimilar Production Mode & Process Analysis

7.4 Infliximab and Biosimilar Sales and Marketing

7.4.1 Infliximab and Biosimilar Sales Channels

7.4.2 Infliximab and Biosimilar Distributors

7.5 Infliximab and Biosimilar Customer Analysis

8 Infliximab and Biosimilar Market Dynamics

8.1 Infliximab and Biosimilar Industry Trends

8.2 Infliximab and Biosimilar Market Drivers

8.3 Infliximab and Biosimilar Market Challenges

8.4 Infliximab and Biosimilar Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Janssen Biotech

Pfizer Inc

Merck

Merck and Co.

List of Tables

Table 1. Global Infliximab and Biosimilar Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Infliximab and Biosimilar Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Infliximab and Biosimilar Market Competitive Situation by Manufacturers in 2024

Table 4. Global Infliximab and Biosimilar Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Infliximab and Biosimilar Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Infliximab and Biosimilar Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Infliximab and Biosimilar Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Infliximab and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Infliximab and Biosimilar, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Infliximab and Biosimilar, Product Type & Application

Table 12. Global Key Manufacturers of Infliximab and Biosimilar, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Infliximab and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infliximab and Biosimilar as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Infliximab and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Infliximab and Biosimilar Sales by Region (2020-2025) & (K Units)

Table 18. Global Infliximab and Biosimilar Sales Market Share by Region (2020-2025)

Table 19. Global Infliximab and Biosimilar Sales by Region (2026-2031) & (K Units)

Table 20. Global Infliximab and Biosimilar Sales Market Share by Region (2026-2031)

Table 21. Global Infliximab and Biosimilar Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Infliximab and Biosimilar Revenue Market Share by Region (2020-2025)

Table 23. Global Infliximab and Biosimilar Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Infliximab and Biosimilar Revenue Market Share by Region (2026-2031)

Table 25. North America Infliximab and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Infliximab and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 27. North America Infliximab and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 28. North America Infliximab and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Infliximab and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Infliximab and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Infliximab and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 32. Europe Infliximab and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 33. Europe Infliximab and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Infliximab and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Infliximab and Biosimilar Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Infliximab and Biosimilar Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Infliximab and Biosimilar Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Infliximab and Biosimilar Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Infliximab and Biosimilar Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Infliximab and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Infliximab and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Infliximab and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Infliximab and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Infliximab and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Infliximab and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Infliximab and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Infliximab and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Infliximab and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Infliximab and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Infliximab and Biosimilar Sales (K Units) by Type (2020-2025)

Table 51. Global Infliximab and Biosimilar Sales (K Units) by Type (2026-2031)

Table 52. Global Infliximab and Biosimilar Sales Market Share by Type (2020-2025)

Table 53. Global Infliximab and Biosimilar Sales Market Share by Type (2026-2031)

Table 54. Global Infliximab and Biosimilar Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Infliximab and Biosimilar Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Infliximab and Biosimilar Revenue Market Share by Type (2020-2025)

Table 57. Global Infliximab and Biosimilar Revenue Market Share by Type (2026-2031)

Table 58. Global Infliximab and Biosimilar Price (USD/Unit) by Type (2020-2025)

Table 59. Global Infliximab and Biosimilar Price (USD/Unit) by Type (2026-2031)

Table 60. Global Infliximab and Biosimilar Sales (K Units) by Application (2020-2025)

Table 61. Global Infliximab and Biosimilar Sales (K Units) by Application (2026-2031)

Table 62. Global Infliximab and Biosimilar Sales Market Share by Application (2020-2025)

Table 63. Global Infliximab and Biosimilar Sales Market Share by Application (2026-2031)

Table 64. Global Infliximab and Biosimilar Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Infliximab and Biosimilar Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Infliximab and Biosimilar Revenue Market Share by Application (2020-2025)

Table 67. Global Infliximab and Biosimilar Revenue Market Share by Application (2026-2031)

Table 68. Global Infliximab and Biosimilar Price (USD/Unit) by Application (2020-2025)

Table 69. Global Infliximab and Biosimilar Price (USD/Unit) by Application (2026-2031)

Table 70. Janssen Biotech Company Information

Table 71. Janssen Biotech Description and Business Overview

Table 72. Janssen Biotech Infliximab and Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Janssen Biotech Infliximab and Biosimilar Product

Table 74. Janssen Biotech Recent Developments/Updates

Table 75. Merck and Co. Company Information

Table 76. Merck and Co. Description and Business Overview

Table 77. Merck and Co. Infliximab and Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Merck and Co. Infliximab and Biosimilar Product

Table 79. Merck and Co. Recent Developments/Updates

Table 80. Pfizer Company Information

Table 81. Pfizer Description and Business Overview

Table 82. Pfizer Infliximab and Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Pfizer Infliximab and Biosimilar Product

Table 84. Pfizer Recent Developments/Updates

Table 85. Key Raw Materials Lists

Table 86. Raw Materials Key Suppliers Lists

Table 87. Infliximab and Biosimilar Distributors List

Table 88. Infliximab and Biosimilar Customers List

Table 89. Infliximab and Biosimilar Market Trends

Table 90. Infliximab and Biosimilar Market Drivers

Table 91. Infliximab and Biosimilar Market Challenges

Table 92. Infliximab and Biosimilar Market Restraints

Table 93. Research Programs/Design for This Report

Table 94. Key Data Information from Secondary Sources

Table 95. Key Data Information from Primary Sources

Table 96. Authors List of This Report

List of Figures

Figure 1. Product Picture of Infliximab and Biosimilar

Figure 2. Global Infliximab and Biosimilar Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Infliximab and Biosimilar Market Share by Type: 2024 & 2031

Figure 4. Infliximab Product Picture

Figure 5. Infliximab-dyyb Product Picture

Figure 6. Infliximab-abda Product Picture

Figure 7. Global Infliximab and Biosimilar Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Infliximab and Biosimilar Market Share by Application: 2024 & 2031

Figure 9. Crohn's Disease

Figure 10. Pediatric Crohn's Disease

Figure 11. Ulcerative Colitis

Figure 12. Rheumatoid Arthritis

Figure 13. Ankylosing Spondylitis

Figure 14. Psoriatic Arthritis

Figure 15. Plaque Psoriasis

Figure 16. Global Infliximab and Biosimilar Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Infliximab and Biosimilar Market Size (2020-2031) & (US$ Million)

Figure 18. Global Infliximab and Biosimilar Sales (2020-2031) & (K Units)

Figure 19. Global Infliximab and Biosimilar Average Price (USD/Unit) & (2020-2031)

Figure 20. Infliximab and Biosimilar Report Years Considered

Figure 21. Infliximab and Biosimilar Sales Share by Manufacturers in 2024

Figure 22. Global Infliximab and Biosimilar Revenue Share by Manufacturers in 2024

Figure 23. Global 5 and 10 Largest Infliximab and Biosimilar Players: Market Share by Revenue in Infliximab and Biosimilar in 2024

Figure 24. Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 25. Global Infliximab and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 26. North America Infliximab and Biosimilar Sales Market Share by Country (2020-2031)

Figure 27. North America Infliximab and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 28. U.S. Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Canada Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Europe Infliximab and Biosimilar Sales Market Share by Country (2020-2031)

Figure 31. Europe Infliximab and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 32. Germany Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. France Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. U.K. Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Italy Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Russia Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Asia Pacific Infliximab and Biosimilar Sales Market Share by Region (2020-2031)

Figure 38. Asia Pacific Infliximab and Biosimilar Revenue Market Share by Region (2020-2031)

Figure 39. China Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Japan Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. South Korea Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. India Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Australia Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Taiwan Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Indonesia Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Thailand Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Malaysia Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Philippines Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America Infliximab and Biosimilar Sales Market Share by Country (2020-2031)

Figure 50. Latin America Infliximab and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 51. Mexico Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Middle East and Africa Infliximab and Biosimilar Sales Market Share by Country (2020-2031)

Figure 55. Middle East and Africa Infliximab and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 56. Turkey Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Saudi Arabia Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. UAE Infliximab and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. Global Sales Market Share of Infliximab and Biosimilar by Type (2020-2031)

Figure 60. Global Revenue Market Share of Infliximab and Biosimilar by Type (2020-2031)

Figure 61. Global Infliximab and Biosimilar Price (USD/Unit) by Type (2020-2031)

Figure 62. Global Sales Market Share of Infliximab and Biosimilar by Application (2020-2031)

Figure 63. Global Revenue Market Share of Infliximab and Biosimilar by Application (2020-2031)

Figure 64. Global Infliximab and Biosimilar Price (USD/Unit) by Application (2020-2031)

Figure 65. Infliximab and Biosimilar Value Chain

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Remicade infliximab Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Remicade Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biosimilar of Remicade Market

Biosimilar Drug Market

Trastuzumab Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Remicade Infliximab Monoclonal Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Generic and Biosimilar Pharmaceuticals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Bevacizumab Biosimilar Market

Global Infliximab Injection Market Research Report 2024

Recombinant Glycosylated Proteins Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Filgrastim and Biosimilars Market Research Report 2024

Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions